The distribution of peripheral blood lymphocyte subsets and its clinical significance in patients with pituitary adenomas
惠国桢,蒋建伟,朱明清,刘卫硕
DOI: https://doi.org/10.3760/cma.j.cn112050-20200910-00507
2021-01-01
Abstract:Objective:To investigate the distribution of T-lymphocyte subsets and natural killer (NK)cells activity in peripheral blood from patients with pituitary adenomas and its clinical significance.Methods:A total of 215 patients with pituitary adenomas who were admitted to Department of Neurosurgery, the First Affiliated Hospital of Soochow University from March 2010 to October 2016 were prospectively enrolled in this study. In the same period, 95 healthy subjects were included as the healthy control group (referred to as the control group). Flow cytometry was used to detect the proportions of CD3 + , CD3 + CD4 + , CD3 + CD8 + , CD3 + CD25 + , CD3 + CD69 + , CD3 + HLA -DR + , CD3 -HLA -DR + and CD3 -CD(16+ 56) + (NK)cells in the peripheral blood of patients with different types of pituitary adenomas and the control group, which were compared between groups. The relationship between different proportions of lymphocyte subsets and clinical characteristics of patients with pituitary adenomas was explored. Results:In the pituitary adenoma group (215 cases), the proportion of CD3 + cells in peripheral blood was lower than that in the control group, while CD3 + CD25 + and CD3 + HLA -DR + cells were higher than the control group, and the differences were statistically significant (all P<0.05). Compared with the control group, (1) the proportion of CD3 + cells in peripheral blood of patients with non-functioning adenoma decreased, while the proportion of CD3 + CD25 + and CD3 + HLA -DR + cells increased (all P<0.05); (2) in the growth hormone(GH) adenoma and prolactin(PRL) adenoma patients, the proportions of CD3 + CD8 + , CD3 + CD25 + and CD3 + HLA -DR + cells increased, while the proportion of NK cells decreased (all P<0.05); (3) in patients with adrenocorticotropic hormone (ACTH) adenomas, the proportions of CD3 + CD4 + cells and NK cells decreased, while the proportions of CD3 + CD8 + , CD3 + CD25 + , CD3 + CD69 + and CD3 + HLA -DR + cells increased (all P<0.05). The proportion of CD3 + cells in the peripheral blood of patients with GH cell adenoma, gonadotropin cell adenoma, and naked cell adenoma (based on the 2017 WHO Classification of Pituitary Adenoma) was lower than that of the control group (all P<0.05). The proportion of NK cells in patients with GH cell adenoma, ACTH cell adenoma, multihormonal and dual hormone cell adenoma was lower than that of the control group (all P<0.05). The proportions of CD3 + CD25 + and CD3 + HLA -DR + cells in patients with GH cell adenoma, ACTH cell adenoma, PRL cell adenoma, gonadotropin cell adenoma, naked cell adenoma, multihormonal and dual hormone cell adenomas were higher than those in the control group (all P<0.05). In the PRL cell adenoma, multihormonal and dual hormone cell adenoma groups, the proportion of CD3 -HLA -DR + cells was lower than that of the control group ( P<0.05). The proportion of CD3 + cells in the giant pituitary adenoma group (tumor diameter >4 cm) was lower than that in the large adenoma group (1-4 cm) and microadenoma group (<1 cm) (both P<0.05). Compared with the non-invasive group, the proportion of CD3 + cells in the invasion group decreased, while the proportion of CD3 + CD25 + cells increased (both P<0.05). The proportion of NK cells in patients with recurrent pituitary adenoma was lower than that in patients with primary pituitary adenoma ( P<0.05). Conclusions:Patients with different types of pituitary adenomas have changes in immune function, which are mainly manifested as the function suppression of cellular immunity or NK cell. The suppression of immune function in patients with pituitary adenomas may be related to tumor burden, tumor invasiveness and recurrence.